News

All News

Press Releases

Media

All Videos

Digital Detail

Independent Corner

Insights

Interviews

Medical World News

Microsites

Peer Exchange

Perfect Consult

Podcasts

Practice Pearls

Student Voices

Webinars/Webcasts

Conferences

Conference Coverage

Conference Listing

Publications

All Publications

Author Submission

Clinical

503B Compounding Pharmacy

ADHD

Allergy

Alzheimer Disease

Anxiety

Asthma

Atopic Dermatitis

Biosimilars

Bipolar Disorder

Brain Health

Breast Cancer

C. Difficile

COPD

COVID Treatment

Cardiovascular Health

Cervical Cancer

Cholangiocarcinoma

Chronic Kidney Disease

Chronic Lymphocytic Leukemia

Colorectal Cancer

Coronavirus

Cough and Cold

Depression

Dermatology

Diabetes

Digestive Health

Dry Eye Disease

Epilepsy

Eye Care

Future of Pharmacy

Gastrointestinal Cancer

Gastrointestinal Health

Gout

Heart Failure

Hematology

Hepatitis

IVIG

Immunization

Immuno-oncology

Infectious Disease

Lung Cancer

Lymphoma

Macular Degeneration

Mental Health

Migraine

Multiple Myeloma

Multiple Sclerosis

Neurology

Neutropenia

Osteoporosis

Ovarian Cancer

Pain Management

Parkinson Disease

Pediatrics

Pharmacy Heroes

Pharmacy Management

Pneumococcal

PrEP

Prostate Cancer

Psoriasis

Psoriatic Arthritis

Reimbursement

Respiratory Syncytial Virus

Rheumatoid Arthritis

Schizophrenia

Skin Cancer

Sleep

Veterinary Pharmacy

Vitamins and Supplements

Weight Management

Women's Health

Zoster

Events

Upcoming Events

Upcoming Webinars

CME/CE

Resources

Cou-Co

Educated Patient

Information for the Pharmacist

Interactive Tools

Partners

Whiteboards

Subscribe

Print Subscription

eNewsletter

Ashley Gallagher is an assistant editor at 

®. She graduated from St. Bonaventure University in 2020 in journalism and mass communications. Previously, she worked as a pharmacy technician for a retail chain.

Articles

Trial results support 5.4 mg/kg of trastuzumab deruxtecan as the optimal dose in individuals with HER2+ metastatic colorectal cancer.

Trastuzumab Deruxtecan Demonstrates Responses Across Advanced Solid Tumors With HER2 Expression

The proposed indications for milvexian include stroke prevention after an acute ischemic stroke or high-risk transient ischemic attack; recent acute coronary syndrome; and atrial fibrillation.

FDA Grants Fast Track Designation to Milvexian for Multiple Prospective Cardiovascular Indications

Recent debates have surrounded whether cognitive deficits, specifically in middle-aged patients, may be driven by cardiovascular and metabolic comorbidities instead of distinct obstructive sleep apnea processes.

Obstructive Sleep Apnea May Have Significant Impact on Cognitive Decline in Middle-Aged Individuals

The proportion of participants with cytomegalovirus disease was 10% with letermovir and 12% with valganciclovir.

FDA Approves New Indication for Letermovir for Prevention of Cytomegalovirus in Adult Kidney Transplant Recipients

Pharmacy Times offers the latest news and insights for the pharmacy professional and solutions that impact the everyday practice of pharmacy.

Whitney D. Maxwell, PharmD, BCPS

Articles